FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Adenocarcinoma

On January 15, 2021, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma who have received a prior trastuzumab-based regimen.

Read the FDA announcement.

Read Daiichi Sankyo's announcement.

Posted 1/19/2021